Advertisement
Advertisement
U.S. markets close in 6 hours 16 minutes
Advertisement
Advertisement
Advertisement
Advertisement

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
394.68+9.14 (+2.37%)
As of 09:42AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close385.54
Open394.94
Bid392.17 x 1100
Ask393.00 x 800
Day's Range392.28 - 395.22
52 Week Range249.50 - 407.93
Volume13,922
Avg. Volume253,253
Market Cap21.894B
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-11.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est441.58
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARGX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • argenx SE
    Daily – Vickers Top Buyers & Sellers for 06/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • GlobeNewswire

    argenx Enters Into Agreement To Acquire Priority Review Voucher

    Amsterdam, the Netherlands – November 30, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an agreement to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) for $102 million. A PRV entitles the holder to FDA priority review of a single Biologics License Application (BLA), which reduces the target review period and may lead to an expedited appr

  • Benzinga

    Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review

    The FDA has accepted Argenx SE's (NASDAQ: ARGX) Biologics License Application for subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG). Under the Priority Review status, the FDA has granted a Prescription Drug User Fee Act (PDUFA) target action date of March 20, 2023. SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme Therapeutics Inc's (NASDAQ: HALO) Enhanze drug delivery technology that facilitates the SC administration of biologics

  • GlobeNewswire

    argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

    - Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 - Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod compared to intravenous (IV) administration November 22, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to

Advertisement
Advertisement